Trends in heart disease mortality among breast cancer survivors in the US, 1975-2017.
Trends in heart disease mortality among breast cancer survivors in the US, 1975-2017.
复制标题
DOI：
10.1007/s10549-022-06515-5
复制
发表时间：
2022-04
影响因子：
3.8
通讯作者：
Veiga L
中科院分区：
文献类型：
--
作者：
Vo JB;Ramin C;Barac A;Berrington de Gonzalez A;Veiga L
Heart disease is a significant concern among breast cancer survivors, in part due to cardiotoxic treatments including chemotherapy and radiotherapy. Long-term trends in heart disease mortality have not been well characterized. We examined heart disease mortality trends among US breast cancer survivors by treatment type. We included first primary invasive breast cancer survivors diagnosed between 1975 and 2016 (aged 18–84; survived 12 + months; received initial chemotherapy, radiotherapy, or surgery) in the SEER-9 Database. Standardized mortality ratios (SMRs) and 10-year cumulative heart disease mortality estimates accounting for competing events were calculated by calendar year of diagnosis and initial treatment regimen. Ptrends were assessed using Poisson regression. All statistical tests were 2-sided. Of 516,916 breast cancer survivors, 40,812 died of heart disease through 2017. Heart disease SMRs declined overall from 1975–1979 to 2010–2016 (SMR 1.01 [95%CI: 0.98, 1.03] to 0.74 [0.69, 0.79], ptrend < 0.001). This decline was also observed for survivors treated with radiotherapy alone and chemotherapy plus radiotherapy. A sharper decline in heart disease SMRs was observed from 1975 to 1989 for left-sided radiotherapy, compared to right-sided. In contrast, there was a non-significant increasing trend in SMRs for chemotherapy alone, and significant by regional stage (ptrend = 0.036). Largest declines in 10-year cumulative mortality were observed from 1975–1984 to 2005–2016 among surgery only: 7.02% (95%CI: 6.80%, 7.23%) to 4.68% (95%CI: 4.39%, 4.99%) and radiotherapy alone: 6.35% (95%CI: 5.95%, 6.77%) to 2.94% (95%CI: 2.73%, 3.16%). We observed declining heart disease mortality trends by most treatment types yet increasing for regional stage patients treated with chemotherapy alone, highlighting a need for additional studies with detailed treatment data and cardiovascular management throughout cancer survivorship. The online version contains supplementary material available at 10.1007/s10549-022-06515-5.
登录
查看更多内容
影响因子：
158.5
作者：
Darby, Sarah C.;Ewertz, Marianne;Hall, Per
通讯作者：
Hall, Per
SEER 治疗数据与医疗保险索赔的比较。
影响因子：
3
作者：
Noone AM;Lund JL;Mariotto A;Cronin K;McNeel T;Deapen D;Warren JL
通讯作者：
Warren JL
影响因子：
51.1
作者：
Darby, SC;McGale, P;Peto, R
通讯作者：
Peto, R
影响因子：
37.8
作者：
Mehta LS;Watson KE;Barac A;Beckie TM;Bittner V;Cruz-Flores S;Dent S;Kondapalli L;Ky B;Okwuosa T;Piña IL;Volgman AS;American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research
通讯作者：
American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research
DOI：
10.1093/jnci/djs317
发表时间：
2012-09-05
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Bowles EJ;Wellman R;Feigelson HS;Onitilo AA;Freedman AN;Delate T;Allen LA;Nekhlyudov L;Goddard KA;Davis RL;Habel LA;Yood MU;McCarty C;Magid DJ;Wagner EH;Pharmacovigilance Study Team
通讯作者：
Pharmacovigilance Study Team